Oxford BioMedica’s (OXB) Buy Rating Reaffirmed at Peel Hunt

Oxford BioMedica (LON:OXB)‘s stock had its “buy” rating restated by equities researchers at Peel Hunt in a research note issued on Tuesday, ThisIsMoney.Co.Uk reports.

LON OXB opened at GBX 691 ($9.03) on Tuesday. The firm has a market capitalization of $475.85 million and a P/E ratio of 63.39. Oxford BioMedica has a 12 month low of GBX 581 ($7.59) and a 12 month high of GBX 1,062.60 ($13.88). The company has a quick ratio of 2.26, a current ratio of 2.44 and a debt-to-equity ratio of 118.46.

In related news, insider Lorenzo Tallarigo purchased 382 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was acquired at an average cost of GBX 695 ($9.08) per share, with a total value of £2,654.90 ($3,469.10). Also, insider Andrew Heath purchased 3,312 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was bought at an average cost of GBX 673 ($8.79) per share, with a total value of £22,289.76 ($29,125.52). Insiders purchased a total of 4,486 shares of company stock valued at $3,028,012 over the last three months.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

See Also: Economic Reports

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.